References
- Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56.e25. doi:https://doi.org/10.1016/j.cell.2017.09.007.
- Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:https://doi.org/10.1016/j.eururo.2016.06.010.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34. doi:https://doi.org/10.3322/caac.21551.
- Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–8. doi:https://doi.org/10.1016/S1470-2045(16)30496-X.
- Balar A, Bellmunt J, O'donnell PH, et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol. 2016;27(Supplement 6):vi567.
- Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–21. doi:https://doi.org/10.1172/JCI80008.
- Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–68. doi:https://doi.org/10.1038/nrclinonc.2017.88.
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–5. doi:https://doi.org/10.1126/science.aar4060.
- Galon J. Immunoscore as a possible new approach for the classification of cancers. Medicographia. 2015;35:334–40.
- Scheel AH, Schäfer SC. Current PD-L1 immunohistochemistry for non-small cell lung cancer. J Thorac Dis. 2018;10(3):1217–9. doi:https://doi.org/10.21037/jtd.2018.02.38.
- McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54. doi:https://doi.org/10.1001/jamaoncol.2015.3638.
- Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med. 2015;12(2):74–8. doi:https://doi.org/10.7497/j.issn.2095-3941.2015.0022.
- Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7(6):1003–15. doi:https://doi.org/10.2217/epi.15.56.
- Højfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12(12):917–30. doi:https://doi.org/10.1038/nrd4154.
- Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–9. doi:https://doi.org/10.1038/70932.
- Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–8. doi:https://doi.org/10.1038/leu.2013.355.
- Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, Golletz C, et al. PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget. 2018;9(1):641–50. doi:https://doi.org/10.18632/oncotarget.23080.
- Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92. doi:https://doi.org/10.1038/nrg3230.
- Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82. doi:https://doi.org/10.1007/s00262-006-0266-z.
- HUANG YIDE, Zhang S-D, McCRUDDEN CIAN, Chan K-W, Lin YAO, Kwok H-F, et al. The prognostic significance of PD-L1 in bladder cancer. Oncology Reports. 2015;33(6):3075–84. doi:https://doi.org/10.3892/or.2015.3933.
- Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y, et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. IJMS. 2017;18(12):2540. doi:https://doi.org/10.3390/ijms18122540.
- Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424 (322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016;7:11406. doi:https://doi.org/10.1038/ncomms11406.